JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online September 16, 2009, 10.2967/jnumed.108.055780
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow All Versions of this Article:
jnumed.108.055780v1
50/10/1655    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ford, E. C.
Right arrow Articles by Wahl, R. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, E. C.
Right arrow Articles by Wahl, R. L.
Journal of Nuclear Medicine Vol. 50 No. 10 1655-1665
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.055780

Continuing Education

18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy*

Eric C. Ford1, Joseph Herman1, Ellen Yorke2 and Richard L. Wahl3

1 Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland; 2 Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York; and 3 Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland

Correspondence: For correspondence or reprints contact: Eric C. Ford, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, 401 N. Broadway, Suite 1440, Baltimore, MD 21231. E-mail: eric.ford{at}jhmi.edu

Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non–small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

Key Words: radiation therapy • IMRT • IGRT • FDG (fluorodeoxyglucose) • FDG PET/CT

* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH OCTOBER 2010.

No potential conflict of interest relevant to this article was reported.

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.